Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR341402 Mix 70/30 versus NovoMix 30 in adults with diabetes mellitus
2017-000092-84Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM) comparing SAR341402 Mix 70/30 with NovoMix 30 (2 arms). Primary endpoint: Change in glycated hemoglobin A1c (HbA1c). Started Apr 2019; status: completed.
02
Drugs
insulin aspartbiphasic insulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-000092-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000092-84.